

The logo for KANEKA, featuring the word "KANEKA" in a bold, blue, sans-serif font. The letters are slightly stylized, with the 'A' and 'E' having unique shapes.

The Dreamology Company
—Make your dreams come true—

A horizontal banner with a blue background. It features a white line graph with multiple peaks and valleys, overlaid on a pattern of small, glowing blue dots. The text "Financial Summary for the Six Months Ended September 30, 2025" is written in white, bold, sans-serif font across the right side of the banner.

Financial Summary **for the Six Months Ended September 30, 2025**

November 12, 2025

KANEKA CORPORATION

I N D E X

FY2025 2Q Summary	01
Highlights	02
Business Performance by Segment	04
Consolidated Balance Sheets	08
Consolidated Cash Flows	09
Earning Forecasts and Other Forward-looking Statements	10
Topics	13

Note :
This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Forecasts of the operating results and other statements contained in this document are forward-looking statements, which are rationally determined based on information currently available to the Company. For a variety of reasons, actual performance may differ substantially from these projections. They do not constitute a guarantee that the Company will achieve these forecasts or any other forward-looking statements.

FY2025 2Q Summary

State of Global Economy – Serious impacts of the U.S. tariff policy developments and heightened geological risks -

- The U.S. :Inflation accelerates, driven by rising prices amid the U.S. tariff policy while moving toward interest rate cuts.
- Europe :Faces temporary slowdown
- China :Economy slump, struggling with weak domestic demand and declining export to the U.S.
- Japan :Depreciation of the yen, rising consumer prices, and an acute labor shortage affected by overseas economic conditions, weighing on corporate earnings

FY2025 *1H Result

Net sales
¥397.4 billion
 (YoY+0.4%)

Operating income
¥15.0 billion
 (YoY▲21.7%)

Net income
¥11.0 billion
 (YoY+8.7%)

- Net sales: year-on-year increase
- Operating income:
 - (Factors for increase) Ongoing sales expansion for Medical
 - (Factors for decrease) Continued sluggishness in Asian market for Vinyls
 Continued stagnation in the European and the U.S. construction demand for MOD and MS
 Delayed recovery and foreign exchange impact for E&I
 Although price revision and a shift toward high value-added products progressed in *2Q, the significant impact of profit decline in *1Q resulted in lower profit for Foods
- Net income: (Factors for increase) Gains on sales of policy-holding shares resulting from reduction of cross-shareholdings, etc

Topics

- Medical: Signed business transfer agreement for Zeon Corporation's medical device business
 ⇒ Business expansion by strengthening the Medical business base

Highlights

	FY2024 1H(Apr.-Sep.)	FY2025 1H(Apr.-Sep.)	(Billions of yen)	
			Difference (YoY)	
			Amount	%
Net sales	396.0	397.4	1.5	0.4%
Operating income	19.1	15.0	(4.1)	(21.7%)
Ordinary income	14.4	11.8	(2.6)	(18.3%)
Net income attributable to owners of parent	10.2	11.0	0.9	8.7%
Operating income margin	4.8%	3.8%		
Net income per share	¥160.48	¥176.51		
Exchange rate (to USD)	¥152.8	¥146.0		
Exchange rate (to EUR)	¥166.1	¥168.1		
Domestic Naptha Price (per kl)	¥78,250	¥65,150		

(Year-on-year)

- **Net sales: Increased**
- **Operating income, ordinary income: Decreased**
- **Net income attributable to owners of parent: Increased**



Business Performance by Segment

(Billions of yen)

	Net sales				Operating income			
	FY2024 1H(Apr.-Sep.)	FY2025 1H(Apr.-Sep.)	Difference		FY2024 1H(Apr.-Sep.)	FY2025 1H(Apr.-Sep.)	Difference	
			Amount	%			Amount	%
Material SU	169.9	162.5	(7.4)	(4.4%)	16.1	12.6	(3.5)	(21.6%)
Quality of Life SU	93.4	97.0	3.6	3.9%	9.6	9.4	(0.1)	(1.2%)
Health Care SU	36.4	37.3	1.0	2.6%	5.4	6.0	0.6	10.3%
Nutrition SU	95.8	100.1	4.3	4.5%	6.4	6.0	(0.5)	(7.7%)
Others	0.4	0.5	0.0	8.1%	0.2	0.2	0.0	11.0%
Adjustment	-	-	-	-	(18.6)	(19.2)	(0.6)	-
Total	396.0	397.4	1.5	0.4%	19.1	15.0	(4.1)	(21.7%)

※SU : Solutions Unit

Performance



(Material Solutions Unit)

**Ongoing weakness in the Asian market for Vinyls,
Stagnant demand in the U.S. housing and construction markets for MOD and MS
⇒ Decreased sales and profits**

Vinyls and Chlor-Alkali

- Performance in 1H: Sales of caustic soda surpassed the year-earlier results, while PVC sales continued to be sluggish in the Asian market.
- Outlook for *2H: Anticipate a recovery in *4Q and beyond.

Performance Polymers (MOD)

- Performance in 1H: Demand adjustments continued in the U.S. housing and construction markets.
- Outlook for 2H: Will promote sales expansion of high value-added products such as non-PVC use and epoxy masterbatch (MX), our differentiated products.

Performance Polymers (MS)

- Performance in 1H: Demand recovering in the European and the U.S. markets after bottomed out in 1Q.
- Outlook for 2H: Expanding sales in Europe and replacing other materials progressed. Expect a global demand recovery.



Green Planet

- Performance in 1H: Customer evaluation for large-scale projects progressed smoothly.
- Outlook for 2H: Will steadily strengthen supply system with a view to significantly increasing sales.

*2H: October 1, 2025 to March 31, 2026

*4Q: January 1 to March 31, 2026

Performance



(Quality of Life Solutions Unit)

Delayed demand recovery for E&I ⇒ Slight decrease in profits

Foam & Residential Techs

- Performance in 1H: Improvement of profit margins through price revision and cost reduction progressed.
- Outlook for 2H: Will continue working to improve profitability for earnings growth.

E & I Technology

- Performance in 1H: Declined earnings of polyimide films and optical acrylic resins due to lower selling prices, rising raw material costs, and foreign exchange impact in 1H.
- Outlook for 2H: Will promote the sales expansion of high-value-added grades, such as high-frequency polyimide and modified optical acrylic resins



PV & Energy management

- Performance in 1H: Firm sales of high-efficiency photovoltaic modules for the domestic residential market.
- Outlook for 2H: Will advance the technology development of tandem-type modules for next-generation photovoltaic module (perovskite), along with the market for building-integrated photovoltaics expanding.

Performance Fibers

- Performance in 1H: Strong sales of hair attachment products. Rising cost of certain raw materials for flame-retardant fabric. Global demand continues to grow steadily.
- Outlook for 2H: Will work on improving profit margins of the flame-retardant fabric.

Performance



(Health Care Solutions Unit)

Ongoing sales expansion for Medical
⇒ Increased sales and profits



Medical

- Performance in 1H: Substantial sales expansion of both blood purification devices and catheters, resulting in the largest earning-generating business. New production facility in Hokkaido (Tomatoh Manufacturing Site for blood purification devices) had already ramped up production.
- Outlook for 2H onward: Construction of a new catheter production facility is making steady progress. Aim to expand the Medical business by strengthening business foundation investment (business transfer for Zeon Corporation's medical device business, in the gastrointestinal and cardiovascular fields).

Pharma

- Performance in 1H: Earnings remained low, partly due to the impact of periodic maintenance on biopharmaceutical production and the delay in closing sales deals.
- Outlook for 2H: Will make progress in the launch and realization of new projects in small molecule pharmaceuticals and biopharmaceuticals
⇒ Significant recovery in earnings in 2H and beyond. We will strengthen R2B both domestically and internationally, focusing on expanding our business domains.

Performance



(Nutrition Solutions Unit)

Expanding sales of Supplement and shifting toward high value-added products in Foods ⇒ Higher sales but lower profits overall

Supplemental Nutrition

- Performance in 1H: Sales of the active form of coenzyme Q10 expanded, particularly in the U.S.
- Outlook for 2H: Sales will further expand in the global market ⇒ Earnings expected to grow steadily.

Foods & Agris

- Performance in 1H: Although profit margins improved through price revisions in 2Q and the shift toward high value-added products, offsetting profit decline in 1Q remained challenging.
- Outlook for 2H: Will promote the shift toward high value-added products and sales expansion of new products in the “Business to Consumer” (B-to-C) business ⇒ Expect to secure earnings at a high level.

Consolidated Balance Sheets

		(Billions of yen)		
		March 31, 2025	September 30, 2025	Difference
Assets	Current assets	444.5	445.8	1.3
	Noncurrent assets	475.6	478.7	3.1
Total assets		920.1	924.5	4.4
Liabilities	Interest bearing debt	203.3	207.1	3.8
	Others	224.4	221.3	(3.1)
	Total liabilities	427.7	428.4	0.7
Net assets	Equity	471.3	474.1	2.8
	Others	21.1	22.1	0.9
	Total net assets	492.4	496.1	3.7
Total liabilities and net assets		920.1	924.5	4.4
Equity ratio		51.2%	51.3%	
Debt equity ratio		0.43	0.44	
Net assets per share		¥7,488.51	¥7,714.59	

- Total assets : Increase in inventories and property, plant and equipment.
- Liabilities : Up primarily due to an increase in loans payable despite a decrease in trade payables.
- Net assets : Up owing chiefly to an increase in retained earnings.
- Equity ratio : 51.3%

Consolidated Cash Flows

	(Billions of yen)	
	FY2024 1H(Apr.-Sep.)	FY2025 1H(Apr.-Sep.)
Cash flows from operating activities	23.0	24.6
Cash flows from investing activities	(30.4)	(15.3)
Free cash flow	(7.4)	9.3
Cash flows from financing activities	1.6	(9.4)
Net increase (decrease) in cash and cash equivalents *	(5.2)	(0.3)
Cash and cash equivalents at end of period	38.1	44.3

* Including Effect of exchange rate change on cash and cash equivalents and Increase (decrease) in cash and cash equivalents resulting from change of scope of consolidation.

- Net cash provided by operating activities : ¥24.6 billion, mainly due to the recording of income before income taxes and depreciation and amortization
- Net cash used in investing activities : ¥15.3 billion, owing primarily to purchase of property, plant and equipment.
- Net cash provided by financial activities : ¥9.4 billion due to cash dividends paid and purchase of treasury shares.
- Cash and cash equivalents as of September 30, 2025 totaled ¥44.3 billion.

Earning Forecasts and Other Forward-looking Statements

(Billions of yen)

	FY2024	FY2025		Difference	
	Result	Previous forecast (May. 14, 2025)	Revised forecast	Vs. previous year	Vs. previous forecast
Net sales	807.2	820.0	800.0	(7.2)	(20.0)
Operating income	40.1	42.0	37.0	(3.1)	(5.0)
Ordinary income	32.9	38.0	31.4	(1.5)	(6.6)
Net income attributable to owners of parent	25.3	33.0	33.0	7.7	-
Operating income margin	5.0%	5.1%	4.6%		
Net income per share	¥400.91	¥524.36	¥534.03		
Dividends per share	¥130	¥160	¥160		
ROE	5.5%	7.2%	7.0%		
Exchange rate (to USD)	¥152.6	¥145.0	¥150.0		
Exchange rate (to EURO)	¥163.9	¥155.0	¥170.0		
Domestic Naptha Price (per kl)	¥75,475	¥70,000	¥65,000		

- ✓ Strengthen Life Science businesses and accelerate portfolio transformation through differentiated technologies.
- ✓ The global economy is facing increasing challenges as U.S. tariff issues intensify, raising concerns over a further prolongation of their impact. Also, uncertain elements such as geopolitical risks and foreign exchange fluctuations remain entrenched.

→ Have revised the forecast for consolidated financial results, which was announced on May 14, 2025.

Aim to achieve the initial net income forecast by promoting capital efficiency.

Earning Forecasts and Other Forward-looking Statements

(Billions of yen)

	Net Sales					Operating Income				
	FY2024	FY2025		Difference		FY2024	FY2025		Difference	
	Result	Previous forecast (May.14, 2025)	Revised forecast	Vs. previous year	Vs. previous forecast	Result	Previous forecast (May.14, 2025)	Revised forecast	Vs. previous year	Vs. previous forecast
Material SU	342.9	337.0	323.0	(19.9)	(14.0)	31.0	31.0	26.8	(4.2)	(4.2)
Quality of Life SU	191.0	196.0	195.0	4.0	(1.0)	20.0	21.0	18.3	(1.7)	(2.7)
Health Care SU	77.3	91.0	84.0	6.7	(7.0)	13.4	17.1	17.0	3.6	(0.1)
Nutrition SU	195.0	195.0	197.0	2.0	2.0	13.1	13.7	14.7	1.6	1.0
Others	1.1	1.0	1.0	(0.1)	-	0.5	0.5	0.4	(0.1)	(0.1)
Adjustment	-	-	-	-	-	(37.9)	(41.3)	(40.2)	(2.3)	1.1
Total	807.2	820.0	800.0	(7.2)	(20.0)	40.1	42.0	37.0	(3.1)	(5.0)

※SU: Solutions Unit

Earning Forecasts and Other Forward-looking Statements

➤ Business forecasts (outlook for 2H)

- ✓ **Material:** Recovery to be expected from 4Q despite ongoing sluggish market in Asia for Vinyls.
Housing and construction markets in the U.S. to recover after bottoming out in 1H for MOD.
Sales to expand in Europe and replace other materials for MS.
- ✓ **QOL:** Improved profit margins to drive profit growth for Foam.
Steady demand for polyimide and acrylic resins to continue, with increased sales of high value-added grades for E&I.
Impacts of higher raw material costs for flame-retardant fabric is expected to gradually ease for Fiber.
- ✓ **Health Care:** Business expansion to progress through new products sales growth, regional expansion (Asia and the U.S), and M&A for Medical.
Sales of new projects for both small molecule and biopharmaceuticals to increase from *3Q, with full-scale recovery expected in 4Q for Pharma.
- ✓ **Nutrition:** Profit margins to be improved. Sales expansion as we enter the peak demand period for Foods.
Market expansion in Asia and Oceania to progress, driven by new product launches (tablet-type coenzyme Q10) for Supplement.

*3Q: October 1 to December 31, 2025

Topics -Expansion of Medical Business-

Signed Business Transfer Agreement for Zeon Corporation’s Medical Device Business

- ✓ Zeon Medical Inc. : Manufacturer with a strong track record and advanced technological capabilities in the gastrointestinal and cardiovascular fields, offering a diverse lineup of products particularly in the gastrointestinal area.
- ✓ Through this acquisition, Kaneka is expected to become the third-largest company (*) in the domestic gastrointestinal market, specifically in endoscopic treatment devices.

<Overview of Business Transfer Counterparty>

Company Name : Zeon Medical Inc.
 Capital : ¥452 million
 Established : 1989

<Overview of Business Transfer Counterparty>

Company Name : River Xemex Co., Ltd.
 Capital : ¥30 million
 Established : 1999

(*) Based on information published in the “Medical Devices and Supplies Yearbook” (issued on June 18, 2025) by R&D Co., Ltd., and includes estimates made by Kaneka based on internal projections. (Sales-based, as of the end of 2025)

Appendix: The List of Kaneka Business Unit Abbreviations

Material SU

Material Solutions Unit

Vinyls

Vinyls & Chlor-Alkali Solutions Vehicle

MOD

Performance Polymers (MOD) Solutions Vehicle

MS

Performance Polymers (MS) Solutions Vehicle

QoL SU

Quality of life Solutions Unit

Foam

Foam & Residential Techs Solutions Vehicle

PV

PV & Energy Management Solutions Vehicle

E & I

E & I Technology Solutions Vehicle

Fiber

Performance Fibers Solutions Vehicle

Health Care SU

Health Care Solutions Unit

Medical

Medical Solutions Vehicle

Pharma

Pharma & Supplemental Nutrition Solutions Vehicle
(Pharma)

Nutrition SU

Nutrition Solutions Unit

Foods

Foods & Agris Solutions Vehicle

Supplement

Pharma & Supplemental Nutrition Solutions Vehicle
(Supplemental Nutrition)

KANEKA CORPORATION
<https://www.kaneka.co.jp/en/>